Optellum Secures TGA Approval for AI Lung Cancer Diagnostic in Australia

The approval of Optellum’s Virtual Nodule Clinic by the Therapeutic Goods Administration (TGA) marks a significant shift in the Australian oncological landscape. As lung cancer remains the leading cause of cancer-related mortality in Australia, the introduction of AI-driven diagnostic support addresses a critical gap in the early detection pipeline. The TGA’s clearance follows similar regulatory successes for Optellum in the United States and Europe, effectively positioning the company as a global leader in AI-assisted lung nodule management. This move is not merely a geographic expansion but a strategic entry into a market that is increasingly prioritizing digital health and automated screening workflows.

At the heart of Optellum’s platform is the Lung Cancer Prediction (LCP) score, an AI-driven metric derived from the analysis of thousands of features within 3D CT scans. Traditionally, radiologists have relied on manual measurements and visual assessments of nodule morphology—factors that are often subjective and prone to inter-observer variability. Optellum’s algorithm provides a standardized, objective risk assessment that helps clinicians differentiate between benign nodules and early-stage malignancies. By providing this decision support, the technology aims to reduce the number of unnecessary, invasive biopsies for benign cases while ensuring that patients with high-risk nodules are fast-tracked to treatment when the disease is most curable.

“

The approval of Optellum’s Virtual Nodule Clinic by the Therapeutic Goods Administration (TGA) marks a significant shift in the Australian oncological landscape.

The timing of this approval is particularly relevant given Australia's recent moves toward establishing a National Lung Cancer Screening Program (NLSCP). Such programs inevitably generate a massive volume of imaging data, often overwhelming existing radiological capacity. AI tools like the Virtual Nodule Clinic are increasingly viewed as essential infrastructure for these programs, acting as a force multiplier for clinicians. By automating the tracking and risk-stratification of nodules over time, Optellum enables a more efficient use of healthcare resources, ensuring that the most urgent cases receive immediate attention without clogging the system with low-risk follow-ups.